208 related articles for article (PubMed ID: 31324389)
41. Advances in proteomics in diffuse large B‑cell lymphoma (Review).
Guo Z; Wang C; Shi X; Wang Z; Tao J; Ma J; Bi L
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38757403
[TBL] [Abstract][Full Text] [Related]
42. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
[No Abstract] [Full Text] [Related]
43. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
44. Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.
Wang D; Liu P; Zhang Y; Liu HY; Shen D; Che YQ
Biomed Res Int; 2018; 2018():1042597. PubMed ID: 30534553
[TBL] [Abstract][Full Text] [Related]
45. Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System.
Veldman-Jones MH; Lai Z; Wappett M; Harbron CG; Barrett JC; Harrington EA; Thress KS
Clin Cancer Res; 2015 May; 21(10):2367-78. PubMed ID: 25301847
[TBL] [Abstract][Full Text] [Related]
46. Quantitative proteomics analysis of differentially expressed proteins in ruptured and unruptured cerebral aneurysms by iTRAQ.
Jiang P; Wu J; Chen X; Ning B; Liu Q; Li Z; Li M; Yang F; Cao Y; Wang R; Wang S
J Proteomics; 2018 Jun; 182():45-52. PubMed ID: 29729990
[TBL] [Abstract][Full Text] [Related]
47. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
48. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
49. A20 promoted the phagocytosis of lymphoma cells by dendritic cells from activated B-cell-like non-Hodgkin lymphoma.
Ha NT; Trang DT; Nhat PV; Huong PT; Giang NH; Mao CV; Binh VD; Vuong NB; Xuan NT
Cell Mol Biol (Noisy-le-grand); 2024 May; 70(5):1-9. PubMed ID: 38814241
[TBL] [Abstract][Full Text] [Related]
50. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
[TBL] [Abstract][Full Text] [Related]
51. [Gene expression profiling of diffuse large B-cell lymphoma in China].
Liu YH; Li L; Liu G; Zhuang HG; Luo DL; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):79-83. PubMed ID: 17493379
[TBL] [Abstract][Full Text] [Related]
52. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
Elfrink S; Ter Beest M; Janssen L; Baltissen MP; Jansen PWTC; Kenyon AN; Steen RM; de Windt D; Hagemann PM; Hess C; van Spronsen DJ; Hoevenaars B; van der Spek E; Xu-Monette ZY; Young KH; Kaffa C; Bervoets S; van Heek J; Hesius E; de Winde CM; Vermeulen M; van den Brand M; Scheijen B; van Spriel AB
Blood Adv; 2022 Apr; 6(7):2254-2266. PubMed ID: 35086136
[TBL] [Abstract][Full Text] [Related]
53. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
54. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
[TBL] [Abstract][Full Text] [Related]
55. Integrated analysis of genome‑wide gene expression and DNA methylation microarray of diffuse large B‑cell lymphoma with TET mutations.
Liu P; Jiang W; Zhao J; Zhang H
Mol Med Rep; 2017 Oct; 16(4):3777-3782. PubMed ID: 28731140
[TBL] [Abstract][Full Text] [Related]
56. Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma.
Zhu D; Fang C; Li X; Geng Y; Li R; Wu C; Jiang J; Wu C
Oncotarget; 2017 Apr; 8(14):23228-23236. PubMed ID: 28423571
[TBL] [Abstract][Full Text] [Related]
57. Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma.
Gao HY; Wu B; Yan W; Gong ZM; Sun Q; Wang HH; Yang W
Oncol Rep; 2017 Sep; 38(3):1363-1372. PubMed ID: 28713985
[TBL] [Abstract][Full Text] [Related]
58. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
59. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Wenzel SS; Grau M; Mavis C; Hailfinger S; Wolf A; Madle H; Deeb G; Dörken B; Thome M; Lenz P; Dirnhofer S; Hernandez-Ilizaliturri FJ; Tzankov A; Lenz G
Leukemia; 2013 Jun; 27(6):1381-90. PubMed ID: 23257783
[TBL] [Abstract][Full Text] [Related]
60. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.
Fornecker LM; Muller L; Bertrand F; Paul N; Pichot A; Herbrecht R; Chenard MP; Mauvieux L; Vallat L; Bahram S; Cianférani S; Carapito R; Carapito C
Sci Rep; 2019 Jan; 9(1):895. PubMed ID: 30696890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
